Xeris Biopharma Holdings, Inc. XERS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.9%+0.5pp | 85.4%+0.9pp | 84.6%+2.3pp | 82.2%0.0pp | 82.2%+0.3pp | |
| Operating margin | 11.4%+2.9pp | 8.5%+5.5pp | 3.1%+7.7pp | -4.7%+6.2pp | -10.9%+6.5pp | |
| Net margin | 3.8%+3.6pp | 0.2%+6.1pp | -5.9%+7.1pp | -13%+7.2pp | -20.3%+6.7pp | |
| EBITDA margin | 11.8%+2.8pp | 9%+5.4pp | 3.5%+7.7pp | -4.2%+6.2pp | -10.3%+6.5pp | |
| Returns | ||||||
| Return on assets | 3.4%+3.2pp | 0.2%+4.7pp | -4.5%+5.1pp | -9.6%+4.2pp | -13.8%+3.2pp | |
| Return on invested capital | 21.4%+6.4pp | 15%+10.4pp | 4.7%+10.9pp | -6.2%+6.8pp | -13%+8.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.1× | 0.8×+0.1× | 0.8×0.0× | 0.7×+0.1× | 0.7×+0.1× | |
| Inventory turnover | 0.7×0.0× | 0.7×0.0× | 0.7×-0.1× | 0.8×-0.1× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.1×-0.1× | 2.2×+0.3× | 1.9×0.0× | 1.9×+0.2× | 1.7×+0.1× | |
| Quick ratio | 1.5×-0.1× | 1.6×+0.2× | 1.3×+0.1× | 1.2×+0.1× | 1.2×0.0× | |
| Cash ratio | 0.9×-0.1× | 1×+0.2× | 0.8×+0.2× | 0.6×0.0× | 0.6×-0.1× | |
| Leverage | ||||||
| Debt-to-assets | 0.7×0.0× | 0.7×0.0× | 0.7×-0.1× | 0.8×-0.1× | 0.9×0.0× | |
| Interest coverage | 1.3×+0.4× | 0.9×+0.6× | 0.3×+0.7× | -0.4×+0.4× | -0.8×+0.4× | |
| Per Share | ||||||
| Book value per share | $0.07-7.6% | $0.08+1,750% | -$0.00+96.0% | -$0.12+47.4% | -$0.23-14.2% | |
| Valuation | ||||||
| Market capitalization | $1.28B+76.9% | $1.3B-0.9% | $1.31B+76.1% | $746.32M-11.7% | $845.13M+67.2% | |
| Enterprise value | $1.42B+52.7% | $1.45B-2.1% | $1.48B+56.8% | $944.26M-10.5% | $1.06B+49.7% | |
| Price / sales | 4.1×+0.8× | 4.5×-0.5× | 4.9×+1.9× | 3×-0.8× | 3.8×+1.3× | |
| EV / sales | 4.5×+0.3× | 5×-0.6× | 5.6×+1.7× | 3.8×-0.9× | 4.7×+1.3× | |
| Earnings yield | 0.9%+7.2pp | 0%+1.2pp | -1.2%+3.1pp | -4.3%+1.0pp | -5.3%+5.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Xeris Biopharma Holdings, Inc. (XERS) runs a 85.9% gross margin and a 11.4% operating margin, with a 3.8% net margin.
- Where do Xeris Biopharma Holdings, Inc.'s ratios come from?
- Every ratio is computed from Xeris Biopharma Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
